Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
Antonios N GargalionisKostas A PapavassiliouDonatella Delle CavePublished in: International journal of molecular sciences (2024)
Lung cancer has been established as the second most common cancer worldwide (most common cancer in men and second most common cancer in women) and as the leading cause of cancer morbidity among neoplasms [...].